Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 5 months from now) | |
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) |
Vemlidy is owned by Gilead Sciences Inc.
Vemlidy contains Tenofovir Alafenamide Fumarate.
Vemlidy has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Vemlidy are:
Vemlidy was authorised for market use on 10 November, 2016.
Vemlidy is available in tablet;oral dosage forms.
Vemlidy can be used as treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older, treatment of chronic hepatitis b in adult patients.
Drug patent challenges can be filed against Vemlidy from 06 November, 2019.
The generics of Vemlidy are possible to be released after 15 February, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Oct 17, 2025 |
New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
M(M-255) | Feb 04, 2023 |
M(M-266) | Aug 22, 2023 |
New Product(NP) | Nov 11, 2019 |
Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 10 November, 2016
Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older
Dosage: TABLET;ORAL